Screener
Neurocrine Biosciences NBIX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's debt-to-equity?
- Neurocrine Biosciences (NBIX) reported debt-to-equity of 0.1× in Q1 2026.
- How has Neurocrine Biosciences's debt-to-equity changed year-over-year?
- Neurocrine Biosciences's debt-to-equity decreased by 30.1% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Neurocrine Biosciences's debt-to-equity?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's debt-to-equity has grown at a 9.3% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Neurocrine Biosciences's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude